TAK 603

Known as: TAK-603 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2006
012319962006

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
BACKGROUND The therapeutic efficacy of the regulation of T helper (Th)-1-predominant immune responses remains to be investigated… (More)
Is this relevant?
2001
2001
Acute graft-versus-host diseases (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic bone marrow… (More)
Is this relevant?
1999
1999
A new antirheumatic, TAK-603, shows nonlinear pharmacokinetics in both animals and humans. To elucidate the mechanism of these… (More)
Is this relevant?
1999
1999
In the course of our studies aimed at obtaining new drugs for treatment of bone and joint diseases, chemical modification of the… (More)
Is this relevant?
1999
1999
A factor in the dose-dependent pharmacokinetics of ethyl 4-(3, 4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2, 4-triazol-1-yl-methyl… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
1998
1998
The disposition of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-1-ylmethyl) quinoline-3-carboxylate (CAS 158146… (More)
Is this relevant?
1998
1998
The metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmeth yl)quinoline -3-carboxylate (1, TAK-603… (More)
Is this relevant?
1998
1998
A double column-switching high-performance liquid chromatographic (HPLC) method for the determination of concentrations for TAK… (More)
Is this relevant?
1997
1997
We have shown that TAK-603, a new anti-rheumatic drug, is more effective in animal models in which cellular immunity plays a… (More)
Is this relevant?
1996
1996
We investigated the pharmacological activities of a newly synthesized anti-rheumatic drug, TAK-603. (1) In vivo: In adjuvant… (More)
Is this relevant?